drugset
drugset / Trial / NCT03634969

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

NCT03634969 ↗

Phase 1 Completed 50 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.

Timeline

Start
2018-08-14
Primary completion
2019-04-30
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986224 Small molecule — —

Indications

heart failure